Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...
March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...
(RTTNews) - Viatris Inc. (VTRS) announced the launch in Canada of Glatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone 20 mg/mL, ...
The US Food and Drug Administration (FDA) has approved a higher-dose, lower-frequency regimen for glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) in the treatment of relapsing-remitting ...
NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Copaxone (glatiramer acetate injection) has potential interactions with other medications. These interactions could cause harmful effects. Copaxone is used in adults to treat relapsing forms of ...
TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results